Biogen to Acquire RayThera for Up to $1B in Immunology Pipeline Deal
BIIB•Biogen agreed to acquire RayThera for up to $1 billion in upfront and milestone payments to gain small-molecule anti-inflammatory drugs targeting immune-mediated diseases. The transaction, expected to close in Q3 2026 pending approvals, marks Biogen’s second major M&A deal this year after its $5.6 billion Apellis acquisition.
1. Deal Terms
Biogen will pay an upfront fee plus milestone payments totaling up to $1 billion for RayThera, with deals tied primarily to clinical and regulatory achievements. The transaction is slated to close in the third quarter of 2026, subject to customary regulatory and shareholder approvals.
2. Pipeline Impact
RayThera’s portfolio focuses on small-molecule therapies for inflammation in immune-related conditions, with its lead candidate scheduled to enter Phase 1 testing in early Q3 2026. Post-close, Biogen will assume responsibility for development, manufacturing and global commercialization of all acquired programs.
3. Strategic Context
This marks Biogen’s second major acquisition of 2026, following the $5.6 billion cash purchase of Apellis plus contingent value rights. The deal underscores Biogen’s strategy to bolster its immunology offerings and expand into new disease areas through targeted M&A.
